Calls for papers
-
Avalyn Pharma said that idiopathic pulmonary fibrosis (IPF) patients who received the higher dose tested in a Phase 1/2 study of the company’s AP01 pirfenidone inhalation solution “had a trend toward stabilization of lung function,”… Read more . . .
-
Armata Pharmaceuticals announced that it plans to initiate clinical development of inhaled AP-PA02, a phage cocktail the company is developing for the treatment of P. aeruginosa infections in cystic fibrosis patients. The SAD portion of the Phase… Read more . . .
-
Liquidia Technologies said that the US Patent Trial and Appeal Board (PTAB) has issued decisions on two patents related to Tyvaso treprostinil inhalation solution, which is marketed by United Therapeutics for the treatment of pulmonary arterial hypertension… Read more . . .
-
With CPhI 2020 having been converted into the virtual “Festival of Pharma” due to the COVID-19 pandemic, the CPhI Pharma Awards ceremony took place online via a live streamed event on October 13. Winners in… Read more . . .
-
Ionis Pharmaceuticals has announced data from a Phase 1 SAD/MAD study of its IONIS-ENAC-2.5Rx nebulized antisense therapy in cystic fibrosis patients demonstrating a mean 55.6% reduction of epithelial sodium channel (ENaC) messenger RNA in cystic fibrosis… Read more . . .
-
Israeli biopharma company Nasus Pharma says that it provided its Taffix intranasal hydroxypropyl methylcellulose (HPMC) powder to members of a synagogue for use during Rosh Hashana celebrations, and worshippers who used Taffix were infected with SARS-CoV-2 at one… Read more . . .
-
Zydus Cadila has announced the launch of its Forglyn formoterol fumarate / glycopyrrolate MDI for the treatment of COPD India. According to Zydus Cadila, the inhaler, which was developed at the company’s Pharmaceutical Technology Center,… Read more . . .
-
Revelation Biosciences announced that the Australian Therapeutic Goods Administration has okayed a Phase 1 clinical study of the company’s REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), which Revelation is developing for the treatment of COVID‑19. According… Read more . . .
-
Aerosol characterization specialist Proveris Scientific has announced that it is working with the University of Sydney and Macquarie University to develop a new method of measuring the surface area of pharmaceutical aerosol particles using optical… Read more . . .
-
A consortium formed by Irish biotech OmniSpirant, nebulizer maker Aerogen, and the National University of Ireland Galway has received a €11.6 million grant from Ireland’s Disruptive Technologies Innovation Fund for development of OS002, an inhaled… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK